Trump's 100% Generic-Drug Threat Doesn't Kick In Until 2028 (Market’s Already Spit Out the Pill)

“Ok grandpa, let’s get you back to bed…” - Big Pharma lobbyists, probably 

August 2028. Drill this into your brain, because that’s when the scariest tariff in pharma is set to go full scorched-Earth. Donny Liberation (read: Trump) is proposing a 100% tariff on imported generic drugs starting that August, rising to 200% in August 2029… a date sharp-eyed readers will notice comes after his term ends. Spoiler: Think of it as a post-dated check, and everyone in Washington knows how often those clear.

In short, starting August 1, imported generics get a two-year grace period at exactly 0%. The stated goal, per the Truth Social: "RESHORE Generic Pharmaceutical Production into America" (the caps lock never rests). In English, build your pill plants on U.S. soil within two years, or your import bill doubles… then doubles again (the rare Washington promise that gets harder with time). The stakes are real, eventually. More than 90% of prescriptions filled in America are generics, and India, twenty years into its run as America's plug trusted supplier of affordable medicines, makes about half of them. So Bloomberg went straight to "low-cost supply threatened," and the fast-money read went straight to "sell Teva."

To be fair, if the full 200% ever lands, that math checks out. Importing pills at triple the sticker becomes a very expensive hobby. But nothing happens until August 2028, and proposals with a two-year fuse have a way of getting lobbied into a fine mist before they ever go off. For the next two years, the scary headline is literally a reprieve. Zero tariff, guaranteed. There's also the small detail that Teva has been trying to leave this marriage since 2023. CEO Richard Francis rebranded the world's biggest generic drugmaker as a "biopharma" company, and the growth now comes from branded drugs… $830 million a quarter of it, up 33%. Telling Teva its generics business is doomed in 2028 is threatening to repossess a car the man already listed on Facebook Marketplace. (Earnings land July 29. Someone will ask. He will not be crying.)

As for the one piece of detail going over every Tom, Dick, and Hairy’s head, a 100% tariff on your competitors' imports is a subsidy with extra steps. The companies already making pills in America, Amphastar and ANI Pharmaceuticals, are the names Jefferies and Citi are pointing at. Every generic that gets priced out of the imports aisle is market share that walks to whoever already owns an American plant.

So the winners mooned, right? Right?! Amphastar sat flat at $19.41 on sleepy volume. ANI slipped about a buck while trading a third of its usual shares. Even Teva, the designated victim, sat at $30.73 like nothing happened. The market’s verdict is that this is a 2028 proposal, file under fiction until further notice. And the tape has a point… Wall Street has never once given a sh*t about a 2028 problem.

For instance, my diet also starts on a date comfortably in the future, so I know exactly what an August 2028 start date is worth. Which means, the watchlist here is short: a domestic manufacturer announcing tariff-driven capacity, or this proposal graduating into formal rulemaking. Either one and Amphastar and ANI become a real trade while Teva's obituary gets shredded. Until then, this tariff is exactly what the label says: extended-release, zero active ingredient for two years, keep away from portfolios. Until next time, friends…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.